Popular Searches:

Your Previous Searches:

Recently Visited Pages:

Home
Equities
Equities
View All Equities
Equities by Sector

Consumer

Energy & Resources

Financials

Healthcare

Industrials

Investment Companies

Metals & Mining

Real Estate

TMT

IRLAB Therapeutics

MCap

SEK653m

Last close

SEK14.10

▲ 1.50 (11.90%)

VolitionRx

MCap

USD51m

Last close

USD0.60

▲ 0.05 (9.82%)

Portobello SpA

MCap

EUR12m

Last close

EUR2.38

▲ 0.20 (9.17%)
Sectors
Sectors
Thematics
Thematics
View All Thematics

Latest
Audiovisual
Audiovisual
View All Audiovisual

Latest

Events
About Edison
About Edison
About Edison

Careers

“Edison’s accessible and high-quality research gives us the opportunity to communicate an independent perspective of Tyman to a wide variety of potential stakeholders.”

Financial Director
Equity Research
Investor Relations
Contact us

IRLAB Therapeutics – executive interview

IRLAB Therapeutics – executive interview

IRLAB Therapeutics — 7 videos in collection

More on this equity

IRLAB Therapeutics is a Sweden-based biotech company focused on developing novel drugs for the treatment of neurodegenerative diseases utilising its integrative screening process technology platform. Its two lead assets, mesdopetam and pirepemat, are in late-stage clinical trials for the symptomatic treatment of Parkinson’s disease (PD). PD is characterised by a triad of cardinal motor symptoms, although non-motor symptoms are as debilitating and remain undertreated. Despite substantial efforts to develop disease-modifying approaches in PD, symptomatic treatment remains the mainstay.

In this interview, CEO Gunnar Olsson provides a recap of IRLAB’s ongoing central nervous system efforts and pipeline.

< Previous

Next >

You may also be interested in these:

Healthcare

23.09.24

IRLAB Therapeutics – executive interview

Healthcare

26.07.24

IRLAB Therapeutics – executive interview

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free